33 31

Cited 0 times in

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Authors
 Kyung-Soo Kim  ;  Byung-Wan Lee 
Citation
 CLINICAL AND MOLECULAR HEPATOLOGY, Vol.26(4) : 430-443, 2020-10 
Journal Title
 CLINICAL AND MOLECULAR HEPATOLOGY 
ISSN
 2287-2728 
Issue Date
2020-10
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.
Files in This Item:
T202004507.pdf Download
DOI
10.3350/cmh.2020.0137
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Byung Wan(이병완) ORCID logo https://orcid.org/0000-0002-9899-4992
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180257
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links